2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2674

Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis
Abstract Number: 1160

Clinical Trials in Rheumatoid Arthritis Have Inadequate Racial/Ethnic, Gender and Age Diversity: A Systematic Review
Abstract Number: 1178

Clinical Utility of DECT in the Diagnosis of Gout at Mayo Clinic in Florida
Abstract Number: 1735

Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Abstract Number: 2066

Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience
Abstract Number: 1552

Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study
Abstract Number: 1820

Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient
Abstract Number: 2197

Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Abstract Number: 2855

Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program
Abstract Number: 2546

Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial
Abstract Number: 2687

Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis
Abstract Number: 2821

Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease
Abstract Number: 1048

Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis
Abstract Number: 791

Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis
Abstract Number: 2636

Cluster Analysis for Classification of Japanese Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Subgroup Analysis of Nationwide Cohort Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].